Introduction: Who Should Undergo Diagnostics and When

People who have achieved remission from acute myeloid leukemia need ongoing diagnostic testing to ensure their disease remains under control. Remission is the medical term used when tests can no longer detect signs of leukemia in the blood or bone marrow, and blood cell counts have returned to normal levels. However, reaching remission does not mean someone is cured or that they can stop all medical care.^[1]

Around two out of three patients with acute myeloid leukemia achieve complete remission after their initial treatment, which is a positive sign that therapy has been effective in destroying the abnormal cells.^[3] Yet even when standard tests show no evidence of disease, some leukemia cells may remain hidden in the body at levels too small to detect. These tiny populations of remaining cells could potentially grow again if not monitored carefully.^[1]

Anyone who has completed intensive treatment for AML should undergo regular diagnostic testing during their remission period. This is particularly important because the cancer can return—a situation known as relapse. Early detection of any returning disease gives doctors and patients the best chance to respond quickly with additional treatment options.^[1]

The frequency and type of diagnostic tests will depend on several factors. Your age, the specific subtype of AML you had, how well you responded to initial treatment, and whether certain genetic or chromosomal changes are present in your leukemia cells all influence your monitoring schedule. Additionally, if you received a stem cell transplant as part of your treatment, you may need different or more frequent testing than someone who had chemotherapy alone.^[2]

Doctors typically recommend that people in remission have check-ups several times per week initially, then monthly, and eventually every few months as time passes. These visits help ensure that if the leukemia does return, it can be caught and treated as early as possible.^[1]

Diagnostic Methods for Monitoring AML in Remission

Understanding remission requires knowing how doctors define and measure it. A patient is considered to be in complete remission when several specific criteria are met. The bone marrow must contain fewer than five percent immature abnormal cells called blasts, blood cell counts must return to normal ranges, and the person should have no symptoms of AML.^[1]

Sometimes doctors use the term “complete remission with incomplete blood count recovery,” which is abbreviated as CRi. This means that while the bone marrow shows fewer than five percent blasts, some blood counts have not yet returned to completely normal levels. Both complete remission and CRi are important milestones, though they represent slightly different states of recovery.^[7]

Blood Tests

Blood tests are the most frequent and least invasive way to monitor someone in remission from AML. During these tests, a healthcare professional draws a small sample of blood from a vein in your arm. The sample goes to a laboratory where specialists count the numbers of different types of blood cells—red blood cells that carry oxygen, white blood cells that fight infection, and platelets that help blood clot.^[1]

The blood count test measures how many of each type of cell you have. Normal levels indicate that your bone marrow is producing healthy cells as it should. If blast cells appear in your blood, or if your counts drop significantly, these could be warning signs that the leukemia is returning. Blood tests also check for certain gene changes and other substances that are specifically found in AML cells.^[1]

Blood testing is typically done at every follow-up appointment. Initially, when you have just entered remission, you might have blood drawn several times a week. As time passes and your remission remains stable, the intervals between blood tests usually lengthen to monthly visits, and eventually to every few months.^[1]

Bone Marrow Biopsy and Aspiration

A bone marrow biopsy is one of the most important diagnostic procedures for monitoring AML in remission. Unlike blood tests that only show what is circulating in your bloodstream, bone marrow tests reveal what is happening in the factory where blood cells are made. Because AML originates in the bone marrow, examining this tissue directly gives doctors the clearest picture of whether any leukemia cells remain.^[4]

During a bone marrow test, your doctor removes a small sample of the spongy tissue from inside your bone, usually from the hip bone. There are actually two parts to this procedure. A bone marrow aspiration involves drawing out liquid marrow with a needle, while a biopsy removes a tiny solid piece of bone and marrow together. Often both are done at the same time to give the most complete information.^[4]

Bone marrow samples are typically taken two to four weeks after starting chemotherapy to see how well the treatment is working. If no leukemia cells are found and blood counts are normal, the doctor will repeat the same tests to confirm that you have achieved remission. After remission is confirmed, bone marrow biopsies are usually performed less frequently than blood tests, but they remain an essential part of long-term monitoring.^[16]

The procedure can be uncomfortable, though local anesthesia is used to numb the area. Many people describe feeling pressure or a brief sharp sensation when the needle enters the bone. The discomfort is usually short-lived, and the valuable information gained makes it worthwhile for monitoring your health.^[4]

Minimal Residual Disease Testing

Minimal residual disease, often shortened to MRD, refers to very small numbers of leukemia cells that may remain in your body even when standard tests show you are in remission. These cells are present in such tiny amounts that regular microscope examination cannot detect them. However, more sensitive laboratory techniques can sometimes find them.^[6]

Testing for minimal residual disease uses advanced methods to look for leukemia cells that standard tests miss. These highly sensitive techniques can detect one cancer cell among thousands or even millions of normal cells. If your test shows positive MRD—meaning these hidden cells are found—your AML may be more likely to come back, and your doctor might recommend additional treatment to try to eliminate these remaining cells.^[6]

When doctors find no evidence of MRD, they may use terms like “complete molecular remission” or “complete molecular response.” This means that even with the most sensitive laboratory tests available, leukemia cells cannot be found in your bone marrow. This is generally a very positive sign, though it still does not guarantee that the disease will never return.^[6]

Genetic and Molecular Testing

Genetic testing examines the chromosomes and genes inside leukemia cells to look for specific mutations or changes. These tests help doctors understand what type of AML you have and how it might behave over time. During remission monitoring, genetic tests can detect whether any cells with these characteristic changes are still present in your blood or bone marrow.^[1]

Certain genetic abnormalities affect how likely your leukemia is to return and how long your remission might last. For example, some chromosome changes offer better chances for long-term remission, while others indicate higher risk of relapse. By tracking these genetic markers over time, your medical team can assess how well your remission is holding and whether you might benefit from additional preventive treatments.^[8]

Diagnostics for Clinical Trial Qualification

If you are considering participating in a clinical trial for AML patients in remission, you will need to undergo specific diagnostic tests to determine whether you qualify for the study. Clinical trials are research studies that test new treatments, and they have strict criteria about who can participate to ensure the study results are reliable and that participants are likely to benefit.^[4]

Most clinical trials for people in remission require documented proof of your remission status. This typically means you must have recent bone marrow test results showing less than five percent blast cells. Blood test results demonstrating normal or near-normal blood cell counts are usually also required. The trial protocol will specify exactly how recent these tests must be—often within two to four weeks of enrolling in the study.^[16]

Many trials also require detailed information about your AML subtype and any genetic or chromosomal abnormalities present in your leukemia cells. Some studies specifically enroll only patients with certain genetic mutations because the treatment being tested is designed to target those particular changes. You may need to have genetic testing done if this information is not already available from your initial diagnosis.^[4]

Clinical trials for AML in remission often test maintenance therapy—treatments given after achieving remission to help prevent relapse. To qualify for these studies, you typically must be in your first complete remission, meaning this is the first time your AML has been brought under control. The trial may also have requirements about how soon after achieving remission you must enroll, and whether you have received certain types of prior treatment such as stem cell transplantation.^[7]

Performance status tests assess how well you can carry out daily activities and how active you are. Most clinical trials require participants to have a certain level of physical function because the study treatments may have side effects that require a degree of baseline health to manage safely. Your doctor will evaluate your overall physical condition as part of the screening process.^[4]

Additional screening tests for clinical trial enrollment might include tests of your heart function, kidney function, and liver function. These ensure that your organs can safely process any medications being studied and that you do not have other health problems that might interfere with the trial or make it dangerous for you to participate. Imaging tests such as CT scans or ultrasounds may also be required to confirm that leukemia has not spread to other parts of your body.^[4]

The informed consent process for clinical trials includes a thorough discussion of all the tests you will need to undergo if you join the study. Trials typically involve more frequent monitoring and more extensive testing than standard care, because researchers need detailed information to evaluate how well the experimental treatment is working. Understanding this time commitment and the testing schedule is an important part of deciding whether to participate.^[4]